$64.90
Buy cagrilintide (AM833) for laboratory research — cagrilintide is a long-acting lipidated analog of human amylin, carrying a fatty-diacid modification that enables albumin binding and a half-life of roughly one week, supplied lyophilized at ≥99% purity.
Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA) built on the 37-amino-acid amylin backbone with stabilising substitutions. Mechanism: it activates amylin receptors — complexes of the calcitonin receptor with receptor activity-modifying proteins — signalling through hindbrain satiety centres including the area postrema, slowing gastric emptying and reducing food intake. Because this pathway is distinct from incretin signalling, cagrilintide is the primary compound in research on amylin-based and combination approaches to energy balance.
In phase 2 monotherapy research, cagrilintide produced dose-dependent mean weight reductions of up to 10.8% at 26 weeks at the highest dose — the strongest result reported for an amylin analog alone. Its principal research profile, however, is in combination: co-administered with semaglutide as CagriSema, the REDEFINE-1 phase 3 trial reported mean weight reductions of 22.7% at 68 weeks in adults with obesity, positioning the amylin-plus-incretin mechanism among the most effective combinations studied in this class.
Cagrilintide’s amylin-receptor pathway is complementary to the GLP-1 receptor activity of semaglutide, which is why the two are studied as a fixed-dose combination. For combination research, the CagriSema stack — cagrilintide + semaglutide pairs both compounds, while triple-agonist comparisons typically reference retatrutide as the single-molecule alternative.
VMAX cagrilintide is supplied as a lyophilized research peptide verified to ≥99% purity by HPLC and mass spectrometry, available in multiple vial sizes selectable on this page.
Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.
For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.
Cagrilintide is a long-acting lipidated amylin analog and dual amylin/calcitonin receptor agonist, studied for satiety signalling, gastric-emptying regulation and combination approaches to energy-balance research.
Cagrilintide is supplied as a lyophilized research compound verified to ≥99% purity by HPLC and mass spectrometry.
Store the lyophilized peptide sealed at -20°C for long-term stability, or 2–8°C short-term. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.
Cagrilintide is an amylin analog acting on amylin and calcitonin receptors, while semaglutide is a GLP-1 receptor agonist. The two engage separate satiety pathways, which is why they are studied together as the CagriSema combination.
No. This material is sold strictly for in-vitro laboratory and preclinical research by qualified personnel. It is not for human or veterinary use.
Cagrilintide is available in multiple vial sizes — select your preferred option on this product page.
| Volume | 10mg, 5mg |
|---|
Reviews
There are no reviews yet.